RxDoctor Payments Data

Misty Hsieh, MD

Family Medicine · Moore, OKNPI 1548204902

Payments from drug & device makers

$1,702in general payments, 2019–2025

Across 120 payments — averaging $14.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$258
  • AstraZeneca$189
  • Teva Pharmaceuticals USA, Inc.$136
  • Lilly USA, LLC$133
  • Boehringer Ingelheim$113
  • Takeda Pharmaceuticals U.S.A., Inc.$113
  • plus $760 from 19 others

What the payments were for

  • Food & beverage$1,702100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,702 in reported general payments places this provider in the 70th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$132,032
Medicare patients
402
Services billed
1,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$80,248
MounjaroTirzepatide31$43,701
JardianceEmpagliflozin25$35,062
EliquisApixaban26$28,346
JanuviaSitagliptin Phosphate13$20,688
RybelsusSemaglutide13$15,537
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$5,810
Rosuvastatin Calcium294$5,275
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$5,060
Atorvastatin Calcium320$4,498
Dexlansoprazole DrDexlansoprazole16$2,988
Omeprazole150$2,721
Levothyroxine Sodium281$2,659
Duloxetine Hcl71$2,519
SynthroidLevothyroxine Sodium43$2,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$56$95,78469 claims
Lilly USA, LLCMounjaro$133$43,70131 claims
Boehringer IngelheimJardiance$113$35,06225 claims
PfizerEliquis$17$28,34626 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$43$2,659281 claims
AbbVieSynthroid$90$2,21043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Moore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →